In phase 2 study of INO-5401 in combination with cemiplimab, Inovio Pharmaceuticals Inc (NASDAQ:INO) achieved success in ensuring the progression-free survival of patients who are diagnosed with GBM (glioblastoma multiforme). The phase 2 study is conducted using INO 9012, and INO 5401 in combination with a PD-1 blocking antibody – Libtayo on fifty-two patients diagnosed […]
Sign Up To Get Our Instant Alerts!
- Japanese Premier Declares COVID-19 State of Emergency in Tokyo 49 views
- Toyota Suspends Production at 2 Plants in Japan Citing Chip Shortage 49 views
- Expect Even More Unique Electric Cars Says Ferrari 43 views
- Kimberly Goldwin Poised to Become Next President of ABC News 30 views
- Private Equity Firm CD&R to Purchase Rest of Cornerstone Building Brands 23 views